Akero Therapeutics Files 8-K on Shareholder Vote
| Field | Detail |
|---|---|
| Company | Akero Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | Jun 4, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: AKRO
TL;DR
AKRO filed an 8-K for a shareholder vote - details to follow.
AI Summary
Akero Therapeutics, Inc. filed an 8-K on June 4, 2025, reporting on a matter submitted to a vote of its security holders. The filing does not detail the specific vote or its outcome, but it is a routine disclosure for such events.
Why It Matters
This filing indicates a formal process involving shareholder decisions, which is a standard corporate governance event.
Risk Assessment
Risk Level: low — This is a routine corporate governance filing and does not appear to contain new material financial or operational information.
Key Players & Entities
- Akero Therapeutics, Inc. (company) — Registrant
- June 3, 2025 (date) — Earliest event reported
- June 4, 2025 (date) — Date of report
FAQ
What specific matter was submitted to a vote of Akero Therapeutics' security holders?
The filing does not specify the exact matter submitted to a vote, only that such a submission occurred.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 3, 2025.
What is Akero Therapeutics' principal executive office address?
The address is 601 Gateway Boulevard, Suite 350, South San Francisco, CA 94080.
What is Akero Therapeutics' telephone number?
The telephone number is (650) 487-6488.
What is the Commission File Number for Akero Therapeutics?
The Commission File Number is 001-38944.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 4, 2025 regarding Akero Therapeutics, Inc..